Asian Journal of Oncology最新文献

{"title":"Herbal and Dietary Supplement Use among Adult Patients Undergoing Treatment at a Tertiary Hospital Cancer Center","authors":"Kevin P. D. A. Enriquez, C. C. Esplana","doi":"10.1055/s-0042-1751115","DOIUrl":"https://doi.org/10.1055/s-0042-1751115","url":null,"abstract":"The use of herbal and dietary supplement in cancer patients has been increasing over the past years, while the risk of its adverse effects and undesirable reactions with conventional treatment has also been accumulating. Limited studies involving perception of herbal and dietary supplements (HDS) by cancer patients have been conducted in our setting. An initial survey was conducted among adult cancer patients undergoing treatment at the Zamboanga City Medical Center (ZCMC) Cancer Institute. HDS users were recruited for focus group discussion (FGD) via purposive sampling. A total of four groups were conducted. Clinical and demographic data were presented through descriptive statistics while data from the FGD were subjected to coding and thematic analysis. Among 22 respondents, more than half (65.4%) of the participants were noted to have used HDS and most (54.5%) were breast cancer patients with stage-II and -III disease. Treatment of cancer, coping with chemotherapy, and relief of symptoms were the major reasons for use. Majority (36.36%) were influenced by the media/internet and most (50%) did not disclose information to their physician. Eight respondents, whose income were below minimum wage, spent more than 25% of their income on HDS, with some having spent more than 50%. This may seriously limit funds and result in failure to adhere to treatment. Among cancer patients in ZCMC, HDS use is widely practiced and half of them do not disclose this information to their physicians. The expenditure on HDS consumes 25 to 50% of the population's meager monthly income. The secrecy surrounding its use and attendant cost may possibly limit adherence and adversely affect outcomes.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48716094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAK2 Mutation and Its Assessment in Relation to Profile of Young Polycythemia Patients in India","authors":"Ankita Bist, Ajay Kandpal, S. A., D. R","doi":"10.1055/s-0042-1750702","DOIUrl":"https://doi.org/10.1055/s-0042-1750702","url":null,"abstract":"\u0000 Purpose The main aim of this study was to detect the presence of JAK2 mutation and its assessment in relation to the clinical, hematological, and mutational profile of young patients with established polycythemia.\u0000 Methods Cross-sectional observational study was undertaken over a period of 1 year in a tertiary care center. Sixty patients were included in our study between the age 18 and 50 years with confirmed diagnosis of polycythemia vera. Reports of all the investigations including bone marrow biopsy and JAK2 mutation testing were assessed.\u0000 Results Presence of JAK2 mutation V617F was found in 38% patients, while bone marrow panmyelosis was present in 67% patients. Higher mean hemoglobin levels were observed in JAK2 mutation-positive patients, compared with those who were negative. Thrombosis-related complications were observed in five patients, all of whom were JAK2 mutation positive, while out of the 18 patients requiring phlebotomy, 15 patients were JAK2 mutation positive.\u0000 Conclusion JAK2 mutation V617F in young Indian population is seen in significantly less cases as compared with Western data, while bone marrow panmyelosis is frequently observed and thus a significant finding for diagnosing polycythemia in our setting. Median hemoglobin was greater for JAK2 mutation-positive cases and so were the phlebotomy requirements and thrombotic events occurrences. Forty-two percent patients had history of some exposure to high-altitude areas adhering to the fact that high altitude is an established risk factor for developing polycythemia and the same is reinforced by our study.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44837312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Vitro Evaluation of Cytotoxicity and Anticancer Activity of Herbal Extract V2S2 (Coded Drug) on Human Cancer Cell Lines","authors":"Sandeep Charak, Monika Sharma, S. Porte","doi":"10.1055/s-0042-1747968","DOIUrl":"https://doi.org/10.1055/s-0042-1747968","url":null,"abstract":"\u0000 Background Cancer is the leading cause of morbidity and mortality worldwide. It encompasses a large family of diseases exhibiting abnormal cell growth with the potential to invade or spread to other part of the body. Natural extracts have been used as an efficient anticancer agent that show promising results. In this, study the cytotoxicity and anticancer effect of Ayurvedic herbal extract code name V2S2 was studied and compared with control drug Adriamycin that is an established chemotherapeutic drug.\u0000 Materials and Methods Ayurvedic coded drug V2S2 is a hydroalcoholic extract of herbs. The in vitro anticancer study was performed with sulforhodamine B assay in TATA Memorial, ACTREC Mumbai as per National Cancer Institute guidelines.\u0000 Result GI50 of V2S2 study drug and Adriamycin on COLO-205, HOP-62, K-562, ISHIKAWA, HeLa, MCF-7, SCC-40, Hep-G2 and MIA-PA-CA-2 is less than 10 that means both drugs have equal anticancer activity.\u0000 Conclusion The study group has more and less equal potential of anticancer activity in compared with a transient's standard anticancer drug. Moreover, in vitro monkey kidney normal cell line study drug V2S2 shows same cytotoxicity as shown by control drug Adriamycin.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41580413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Plasma Cell Myeloma with Multilobated and Monocytoid Morphology","authors":"Sneha Kakoty, Anurag Saha, Torsha Jana, Jyoti Sawhney","doi":"10.1055/s-0042-1750793","DOIUrl":"https://doi.org/10.1055/s-0042-1750793","url":null,"abstract":"Plasma cell myeloma (PCM) accounts for approximately 1% of malignant tumors and 10 to 15% of hematological neoplasms. It is a malignant disease characterized by abnormal proliferation of plasma cells and monoclonal immunoglobulins or free light chains (FLCs). There are many morphological variations of the myeloma plasma cells which include mature, immature, plasmablastic, and pleomorphic types. Here, we report a rare presentation of PCM with normal serum protein electrophoresis but elevated serum FLCs and having convoluted, multilobated, and monocytoid morphology. This type of morphology is related to an aggressive clinical course and resistance to conventional chemotherapy. Moreover, absence of M protein in serum/urine electrophoresis does not rule out the diagnosis of PCM and serum FLC assays plays an important role in this kind of scenarios.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46226461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenging Management of Large Aggressive Fibromatosis of the Anterior Abdominal Wall: A Case Report","authors":"R. Salah, Kamal El Mokhtari, A. Bennis, O. Zaddoug, M. Benchakroun, A. Zine, M. Tanane, S. Bouabid","doi":"10.1055/s-0042-1750791","DOIUrl":"https://doi.org/10.1055/s-0042-1750791","url":null,"abstract":"Aggressive fibromatosis is a rare and benign tumor of soft tissues, locally invasive but never metastasizes. This proliferation arises in musculoaponeurotic structures. It is more common in young fertile women due to hormonal influences. Radical resection with free margins is the key to an effective outcome. We present here the case of a 47-year-old woman, without medical history, who was referred to our hospital for a painful swelling of the left iliac fossa, diagnosed with aggressive fibromatosis of the anterior abdominal wall based on radiological and histological findings. She underwent an excision of the mass with free margins followed by reconstruction of the musculo-fascial defect. After a follow-up of 12 months, there was no evidence of recurrence. Management of aggressive fibromatosis remains a challenge for surgeons. Complete excision of the tumor followed by reconstruction of abdominal wall defect is the first choice of treatment.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47185364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supplementation with Cod Liver Oil Capsules Reduces Weight Loss and Mucositis in Head and Neck Cancer Patients Undergoing Curative Radiotherapy without Affecting the Treatment Response","authors":"S. Hegde, S. Rao, Rhea Katherine D’souza, M. Baliga","doi":"10.1055/s-0042-1750019","DOIUrl":"https://doi.org/10.1055/s-0042-1750019","url":null,"abstract":"\u0000 Background Weight loss is a common observation in head and neck cancer (HNC) patients and the severity depends on the modalities used. The purpose of this study was to evaluate the effectiveness of providing two capsules of fish oil supplement each day during the course of curative radiotherapy for HNC patients.\u0000 Materials and Methods This was a retrospective single-center study, and files of HNC patients treated with radiotherapy between the months of January 2015 and March 2015 were evaluated. Data on gender, age, tumor, treatment details, adverse effects, weight before and at the end of the treatment, and treatment response were obtained from the patient files. The data collected were entered into Excel sheet and subjected to statistical analysis using chi-square tests, unpaired t-test, and analysis of variance with post hoc Tukey test. A p-value of <0.05 was considered significant.\u0000 Results Records of 68 patients treated during the study period with radiation for HNC and admitted to the inpatient facility throughout the treatment period were retrospectively reviewed. Majority of the patients had advanced stage tumors. There was no difference in the initial weight of the patients in the two groups while a significant difference was seen in the final weight (p = 0.007). The number of patients with severe weight loss (>5 kg) was more in the control than in the fish oil cohort (68.89 vs. 43.48) and was significant (p = 0.042). In addition to this, the incidence of mucositis was delayed and also lesser in severity in the cohorts that had received fish oil. At the dose used, fish oil capsules did not have any adverse effects and importantly there was no significant difference in treatment response.\u0000 Conclusion The results of the study indicate that administering fish oil capsules was effective in arresting weight loss and delaying and mitigating mucositis in HNC patients undergoing curative radiotherapy. Fish oil capsule has good safety profile, was devoid of any toxic effects, and has a good clinical application value.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46042036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous Modulated Accelerated Radiotherapy (SMART) with Dysphagia Aspiration-Related Structures (DARS) Sparing: Do We Have a Role for Dose Condensation in Locally Advanced Head and Neck Cancer","authors":"Bindhu Joseph, M. Ramachandran, N. Valuvil, L. Vishwanath","doi":"10.1055/s-0042-1745730","DOIUrl":"https://doi.org/10.1055/s-0042-1745730","url":null,"abstract":"\u0000 Introduction Concurrent chemotherapy integrated with intensity-modulated radiotherapy (IMRT) is the standard of care for locally advanced head and neck cancer. Simultaneous integrated boost technique has allowed differential doses to primary and normal structures permitting significant toxicity reduction. The current study explores the feasibility of the simultaneous modulated accelerated radiotherapy (SMART) technique to enhance cytoreduction and explore the possibility of dose intensification with radiobiologically targeted treatment condensation.\u0000 Methods Thirty patients were randomized in an open-labeled study to receive concurrent chemoradiation of 60 Gy in 25 fractions with “SMART” technique or 70 Gy in 35 fractions using conventional intensity-modulated radiotherapy simultaneous integrated boost “IMRT SIB.” The primary endpoints included comparative volumetric cytoreduction between the study and control arm assessed during the course of treatment and final response evaluation. Secondary endpoints involved the assessment of acute toxicity parameters for xerostomia, mucositis, dysphagia, and fatigue.\u0000 Results The “SMART” study arm showed comparable volumetric cytoreduction to the conventional “IMRT SIB” arm at midtreatment (p-value = 0.225) as well as toward completion (p-value = 0.476). The study arm did observe 94.4% cytoreduction of tumor volume compared with 88.05% in the conventional arm at the time of response evaluation. In spite of treatment condensation, there was no significant increase in toxicity with “SMART.” There was no difference in the frequency or duration of grade 3 mucositis in the “SMART” arm in spite of intensification (p-value = 0.728). In the “SMART” arm, there was a favorable reduction in the duration of grade ⅔ dysphagia; 2.8 weeks versus 4.6 weeks (p-value = 0.002). Even though the xerostomia was comparable in frequency and intensity, the total duration of xerostomia was 50% less (p-value = 0.001).\u0000 Conclusions The “SMART” technique provides a radiobiologically sound, effective, and safe protocol that has the potential to improve the treatment of locally advanced head and neck cancer. The good tolerability and toxicity profile in the study arm is encouraging and facilitates further research.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44650501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Approach to the Diagnosis of Hepatoid Adenocarcinoma, an Under-reported Entity: Case Series and Review of Literature","authors":"P. Chhabra, S. Sancheti, A. Sali, P. Somal, Aishwarya Sharma, R. Brar, Rakesh Gulia, Rakesh Kapoor","doi":"10.1055/s-0042-1748629","DOIUrl":"https://doi.org/10.1055/s-0042-1748629","url":null,"abstract":"Hepatoid adenocarcinoma is a rare type of extra-hepatic adenocarcinoma which exhibits morphological, functional, and immunohistochemical features of hepatocellular carcinoma, hence correct diagnosis poses a challenge. The most frequent site of this tumor is stomach and rarely occurs in ovaries, lung, gallbladder, pancreas, uterus, and other sites. We present four cases of hepatoid adenocarcinoma of our hospital at rare sites like lungs and gallbladder along with literature review and a simplified approach to diagnosis. In absence of adequate immunohistochemistry or radiological findings often this entity is missed or misdiagnosed as metastatic hepatocellular carcinoma. We have analyzed these hepatoid adenocarcinoma cases in terms of various clinical, serological, histo-morphological, and immunohistochemical parameters, and propose a systematic approach to correctly diagnose this entity.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43794888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Radiological Curiosity of a Rare Diagnosis: Lhermitte- Duclos Disease","authors":"Wilson Bizimana, Rita Oze Koudouhonon, S. Igombe, Waïs A Amarkak, K. Benelhosni, I. Nassar, N. Moatassim","doi":"10.1055/s-0042-1748638","DOIUrl":"https://doi.org/10.1055/s-0042-1748638","url":null,"abstract":"Lhermitte–Duclos disease (LDD) is a rare cerebellar lesion, described in 1920 by two French physicians: Lhermitte and Duclos. The clinical presentation is usually made of neurological symptoms. This lesion is characterized by a hamartomatous lesion in the posterior fossa. Mainly diagnosed by MRI, when it comes to preoperative, the T2-weightened MRI demonstrates the classical “tiger-striped” pattern. The definitive diagnosis, nonetheless, is histopathological. The treatment for LDD consists of surgical decompression or excision. We present here a rare case of a woman who developed neurological symptoms that led to LDD diagnosis to describe protocol MRI imaging, the main findings and their pathophysiological meanings.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45036615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Triple-Negative Breast Cancer Patients in Response to Taxane and Nontaxane-Based Neoadjuvant Chemotherapies","authors":"Mohsin Khan, Zarmina Alam, Shahid Ali Siddiqui, Mohd Akram, M. Alam","doi":"10.1055/s-0042-1750086","DOIUrl":"https://doi.org/10.1055/s-0042-1750086","url":null,"abstract":"\u0000 Introduction Neoadjuvant chemotherapy (NAC) is the standard of care for locally advanced breast cancer. The achievement of pathological complete response (pCR) in response to NAC is of clinical significance as it correlates with improved long-term outcome. pCR rate varies with different chemotherapeutic agents and a higher rate may be associated with higher treatment cost and more toxicity.Triple-negative breast cancer (TNBC) has poorer prognosis than non-TNBC (estrogen receptor, progesterone receptor, and/or human epidermal growth factor receptor 2 expressing tumors), but patients achieving pCR may have similar outcome. We evaluated the response of TNBC after taxane and nontaxane-based NAC and its correlation with survival outcome.\u0000 Materials and Methods This was a retrospective study comparing the efficacy of “taxotere, Adriamycin and cyclophosphamide TAC” versus “cyclophosphamide, epirubicin, 5-fluorouracil/cyclophosphamide, Adriamycin, 5-fluorouracil (CEF/CAF)” NAC regimens in patients with locally advanced TNBC. The efficacy and safety of both the regimens were compared. Overall and disease-free survival were analyzed.\u0000 Results Two-hundred and forty-nine eligible patients were included and divided into two groups: taxane group receiving “TAC” regimen (123 patients) and nontaxane group receiving “CEF/CAF” regimen (126 patients). A higher pCR rate was achieved with taxane compared with nontaxane NAC (28 vs. 12%) (p = 0.0001). Although taxane addition did not lead to survival advantage for the entire group, significantly better survival rates were achieved for patients who had pCR compared with similar subgroup of patients in nontaxane group. Both the NAC regimens were well tolerable.\u0000 Conclusion Taxane-based NAC was although costlier than anthracycline-based regimen but was more effective, resulting in a higher pCR rate and an improved survival outcome in patients who achieved pCR.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41782671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}